A critical review on HE4 performance in endometrial cancer: Where are we now?

Tumor Biology

Volumn 35, Issue 2, 2014, Pages 881-887

  Angioli, Roberto ^a   Miranda, Andrea ^a   Aloisi, Alessia ^a   Montera, Roberto ^a   Capriglione, Stella ^a   De Cicco Nardone, Carlo ^a   Terranova, Corrado ^a   Plotti, Francesco ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Endometrial cancer; HE4; Review; Tumor marker

Indexed keywords

HUMAN EPIDIDYMIS PROTEIN 4;

AREA UNDER THE CURVE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FOLLOW UP; HUMAN; MEDLINE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TUMOR INVASION;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84898893831     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1190-4     Document Type: Review

References (23)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet. 2000;355(9213):1404-11.
3. Papanikolaou A, Kalogiannidis I, Goutzioulis M, Misailidou D, Makedos A, Vergote I, et al. Pelvic lymphadenectomy as alternative to postoperative radiotherapy in high risk early stage endometrial cancer. Arch Gynecol Obstet. 2006;274(2):91-6.
4. Smith-Bindman R, Weiss E, Feldstein V. How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound Obstet Gynecol. 2004;24(5):558-65.
5. Li J, Dowdy S, Tipton T, Podratz K, Lu WG, Xie X, et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn. 2009;9(6):555-66.
6. Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642-6.
7. Fujimoto T, Nanjyo H, Fukuda J, Nakamura A, Mizunuma H, Yaegashi N, et al. Endometrioid uterine cancer: histopathological risk factors of local and distant recurrence. Gynecol Oncol. 2009;112(2):342-7.
8. Hernandez E. American college of obstericians and gynecologists. ACOG practice bulletin number 65: management of endometrial cancer. Obstet Gynecol. 2006;107(4):952.
9. Emons G, Kimmig R. Uterus commission of the gynecological oncology working group (AGO). Interdisciplinary S2k guidelines on the diagnosis and treatment of endometrial carcinoma. J Cancer Res Clin Oncol. 2009;135(10):1387-91.
10. Ward JH. NCCN guidelines and the international community. J Natl Compr Canc Netw. 2011;9(2):133-4.
11. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008;110(2):196-201.
12. Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer. 2011;104(9): 1418-25.
13. Moore RG, Miller CM, Brown AK, Robison K, Steinhoff M, Lambert-Messerlian G. Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus. Int J Gynecol Cancer. 2011;21(7):1185-90.
14. Kalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J, et al. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol. 2012;124(2): 270 - 5.
15. Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C, et al. HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol. 2012;126(2):186-91.
16. Zanotti L, Bignotti E, Calza S, Bandiera E, Ruggeri G, Galli C, et al. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. Clin Chem Lab Med. 2012;50(12):2189-98.
17. Angioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R, et al. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumour Biol. 2013;34(1):571-6.
18. Saarelainen SK, Peltonen N, Lehtimäki T, Perheentupa A, Vuento MH, Mäenpää JU. Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma. Am J Obstet Gynecol. 2013;209(2):142. e1-6.
19. Omer B, Genc S, Takmaz O, Dirican A, Kusku-Kiraz Z, Berkman S, Gurdol F. The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients. Tumour Biol. 2013 May 3.
20. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10-7.
21. Kew FM, Roberts AP, Cruickshank DJ. The role of routine follow-up after gynecological malignancy. Int J Gynecol Cancer. 2005;15(3): 413-9.
22. Lajer H, Jensen MB, Kilsmark J, Albæk J, Svane D, Mirza MR, et al. The value of gynecologic cancer follow-up: evidence-based ignorance? Int J Gynecol Cancer. 2010;20(8):1307-20.
23. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:105-43.